Get started
4D Molecular Therapeutics, Inc.4D Molecular Therapeutics, Inc.4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

FDMT chart


Full chart

FDMT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪142.61 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.16 USD
Net income (FY)
‪−160.87 M‬ USD
Revenue (FY)
‪37.00 K‬ USD
Shares float
‪39.64 M‬
Beta (1Y)
0.65

Employees


Employees (FY)
227
Change (1Y)
+80 +54.42%
Revenue / Employee (1Y)
163.00 USD
Net income / Employee (1Y)
‪−708.67 K‬ USD

About 4D Molecular Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
David H. Kirn
Website
4dmoleculartherapeutics.com
Headquarters
Emeryville
Founded
2013
FIGI
BBG00QG40R88
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

FDMT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as FDMT.

Frequently Asked Questions


The current price of FDMT is 3.08 USD — it has increased by 0.65% in the past 24 hours. Watch 4D Molecular Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange 4D Molecular Therapeutics, Inc. stocks are traded under the ticker FDMT.
FDMT stock has risen by 15.36% compared to the previous week, the month change is a −16.30% fall, over the last year 4D Molecular Therapeutics, Inc. has showed a −87.48% decrease.
We've gathered analysts' opinions on 4D Molecular Therapeutics, Inc. future price: according to them, FDMT price has a max estimate of 51.00 USD and a min estimate of 6.00 USD. Watch FDMT chart and read a more detailed 4D Molecular Therapeutics, Inc. stock forecast: see what analysts think of 4D Molecular Therapeutics, Inc. and suggest that you do with its stocks.
FDMT reached its all-time high on Feb 11, 2021 with the price of 55.11 USD, and its all-time low was 2.24 USD and was reached on Apr 9, 2025. View more price dynamics on FDMT chart.
See other stocks reaching their highest and lowest prices.
FDMT stock is 9.80% volatile and has beta coefficient of 0.65. Track 4D Molecular Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is 4D Molecular Therapeutics, Inc. there?
Today 4D Molecular Therapeutics, Inc. has the market capitalization of ‪142.61 M‬, it has increased by 12.32% over the last week.
Yes, you can track 4D Molecular Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
4D Molecular Therapeutics, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
FDMT earnings for the last quarter are −0.89 USD per share, whereas the estimation was −0.84 USD resulting in a −6.53% surprise. The estimated earnings for the next quarter are −0.87 USD per share. See more details about 4D Molecular Therapeutics, Inc. earnings.
4D Molecular Therapeutics, Inc. revenue for the last quarter amounts to 500.00 USD, despite the estimated figure of ‪1.42 M‬ USD. In the next quarter, revenue is expected to reach ‪455.31 K‬ USD.
FDMT net income for the last quarter is ‪−49.67 M‬ USD, while the quarter before that showed ‪−43.84 M‬ USD of net income which accounts for −13.29% change. Track more 4D Molecular Therapeutics, Inc. financial stats to get the full picture.
No, FDMT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 227 employees. See our rating of the largest employees — is 4D Molecular Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. 4D Molecular Therapeutics, Inc. EBITDA is ‪−181.14 M‬ USD, and current EBITDA margin is ‪−489.56 K‬%. See more stats in 4D Molecular Therapeutics, Inc. financial statements.
Like other stocks, FDMT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade 4D Molecular Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So 4D Molecular Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating 4D Molecular Therapeutics, Inc. stock shows the sell signal. See more of 4D Molecular Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.